Does the media prefer SABS or MNKD?

In the previous week, MannKind had 3 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 4 mentions for MannKind and 1 mentions for SAB Biotherapeutics. MannKind's average media sentiment score of 0.68 beat SAB Biotherapeutics' score of 0.00 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SAB Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MannKind 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MLTX or SABS more profitable?

SAB Biotherapeutics' return on equity of -6.74% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MoonLake Immunotherapeutics N/A -82.53% -58.17% SAB Biotherapeutics N/A -6.74% -6.06%

Is SABS or ODTX more profitable?

Odyssey Therapeutics' return on equity of 0.00% beat SAB Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets SAB Biotherapeutics N/A -6.74% -6.06% Odyssey Therapeutics N/A N/A N/A

Does the media prefer SABS or ODTX?

In the previous week, Odyssey Therapeutics had 11 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 12 mentions for Odyssey Therapeutics and 1 mentions for SAB Biotherapeutics. Odyssey Therapeutics' average media sentiment score of 0.93 beat SAB Biotherapeutics' score of 0.00 indicating that Odyssey Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SAB Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Odyssey Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CRVS or SABS more profitable?

SAB Biotherapeutics' return on equity of -6.74% beat Corvus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corvus Pharmaceuticals N/A -36.15% -33.62% SAB Biotherapeutics N/A -6.74% -6.06%

Does the media favor CRVS or SABS?

In the previous week, Corvus Pharmaceuticals had 6 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 7 mentions for Corvus Pharmaceuticals and 1 mentions for SAB Biotherapeutics. Corvus Pharmaceuticals' average media sentiment score of 0.98 beat SAB Biotherapeutics' score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SAB Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor GLUE or SABS?

In the previous week, Monte Rosa Therapeutics had 10 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 11 mentions for Monte Rosa Therapeutics and 1 mentions for SAB Biotherapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.15 beat SAB Biotherapeutics' score of 0.00 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SAB Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

SAB Biotherapeutics (SABS) Competitors

$3.72 -0.03 (-0.80%)

As of 09/3/2026 04:00 PM Eastern

Compare

SABS vs. MNKD, MLTX, ODTX, CRVS, and GLUE

Should you buy SAB Biotherapeutics stock or one of its competitors? SAB Biotherapeutics's main competitors and comparable companies include MannKind (MNKD), MoonLake Immunotherapeutics (MLTX), Odyssey Therapeutics (ODTX), Corvus Pharmaceuticals (CRVS), and Monte Rosa Therapeutics (GLUE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does SAB Biotherapeutics compare to MannKind?

SAB Biotherapeutics (NASDAQ:SABS) and MannKind (NASDAQ:MNKD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

In the previous week, MannKind had 3 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 4 mentions for MannKind and 1 mentions for SAB Biotherapeutics. MannKind's average media sentiment score of 0.68 beat SAB Biotherapeutics' score of 0.00 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MannKind	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SAB Biotherapeutics has a net margin of 0.00% compared to MannKind's net margin of -11.08%. SAB Biotherapeutics' return on equity of -6.74% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
MannKind	-11.08%	-11.21%	-6.31%

SAB Biotherapeutics has higher earnings, but lower revenue than MannKind. MannKind is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	256.43	$13.27M	-$1.30	N/A
MannKind	$348.97M	3.65	$5.86M	-$0.13	N/A

SAB Biotherapeutics currently has a consensus target price of $12.00, indicating a potential upside of 222.58%. MannKind has a consensus target price of $9.22, indicating a potential upside of 132.80%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe SAB Biotherapeutics is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 7.4% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 2.6% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

SAB Biotherapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, MannKind has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

Summary

SAB Biotherapeutics beats MannKind on 10 of the 16 factors compared between the two stocks.

How does SAB Biotherapeutics compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

SAB Biotherapeutics' return on equity of -6.74% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%
SAB Biotherapeutics	N/A	-6.74%	-6.06%

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

MoonLake Immunotherapeutics presently has a consensus price target of $24.57, suggesting a potential upside of 61.76%. SAB Biotherapeutics has a consensus price target of $12.00, suggesting a potential upside of 222.58%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe SAB Biotherapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, SAB Biotherapeutics had 1 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 1 mentions for SAB Biotherapeutics and 0 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.00 equaled SAB Biotherapeutics'average media sentiment score.

Company	Overall Sentiment
MoonLake Immunotherapeutics	Neutral
SAB Biotherapeutics	Neutral

SAB Biotherapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
SAB Biotherapeutics	$1.32M	256.43	$13.27M	-$1.30	N/A

MoonLake Immunotherapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Summary

SAB Biotherapeutics beats MoonLake Immunotherapeutics on 9 of the 13 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Odyssey Therapeutics?

SAB Biotherapeutics (NASDAQ:SABS) and Odyssey Therapeutics (NASDAQ:ODTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

In the previous week, Odyssey Therapeutics had 11 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 12 mentions for Odyssey Therapeutics and 1 mentions for SAB Biotherapeutics. Odyssey Therapeutics' average media sentiment score of 0.93 beat SAB Biotherapeutics' score of 0.00 indicating that Odyssey Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Odyssey Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.8% of SAB Biotherapeutics shares are held by institutional investors. 7.4% of SAB Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

SAB Biotherapeutics has higher revenue and earnings than Odyssey Therapeutics. Odyssey Therapeutics is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	256.43	$13.27M	-$1.30	N/A
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A

SAB Biotherapeutics currently has a consensus target price of $12.00, indicating a potential upside of 222.58%. Odyssey Therapeutics has a consensus target price of $35.75, indicating a potential upside of 35.42%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe SAB Biotherapeutics is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Odyssey Therapeutics' return on equity of 0.00% beat SAB Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
Odyssey Therapeutics	N/A	N/A	N/A

Summary

SAB Biotherapeutics beats Odyssey Therapeutics on 8 of the 12 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Corvus Pharmaceuticals presently has a consensus target price of $33.33, indicating a potential upside of 127.53%. SAB Biotherapeutics has a consensus target price of $12.00, indicating a potential upside of 222.58%. Given SAB Biotherapeutics' higher possible upside, analysts clearly believe SAB Biotherapeutics is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

SAB Biotherapeutics' return on equity of -6.74% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%
SAB Biotherapeutics	N/A	-6.74%	-6.06%

In the previous week, Corvus Pharmaceuticals had 6 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 7 mentions for Corvus Pharmaceuticals and 1 mentions for SAB Biotherapeutics. Corvus Pharmaceuticals' average media sentiment score of 0.98 beat SAB Biotherapeutics' score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SAB Biotherapeutics has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A
SAB Biotherapeutics	$1.32M	256.43	$13.27M	-$1.30	N/A

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Corvus Pharmaceuticals has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

Summary

Corvus Pharmaceuticals beats SAB Biotherapeutics on 8 of the 15 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

SAB Biotherapeutics has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. SAB Biotherapeutics' return on equity of -6.74% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
SAB Biotherapeutics	N/A	-6.74%	-6.06%

SAB Biotherapeutics has lower revenue, but higher earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	9.92	-$38.63M	-$1.76	N/A
SAB Biotherapeutics	$1.32M	256.43	$13.27M	-$1.30	N/A

Monte Rosa Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

Monte Rosa Therapeutics presently has a consensus target price of $28.50, suggesting a potential upside of 98.19%. SAB Biotherapeutics has a consensus target price of $12.00, suggesting a potential upside of 222.58%. Given SAB Biotherapeutics' higher possible upside, analysts plainly believe SAB Biotherapeutics is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by company insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Monte Rosa Therapeutics had 10 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 11 mentions for Monte Rosa Therapeutics and 1 mentions for SAB Biotherapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.15 beat SAB Biotherapeutics' score of 0.00 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

SAB Biotherapeutics beats Monte Rosa Therapeutics on 10 of the 17 factors compared between the two stocks.

Get SAB Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SABS vs. The Competition

Export

Metric	SAB Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$341.20M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-2.86	12.66	273.28	25.38
Price / Sales	256.43	1,309.16	613.48	92.60
Price / Cash	10.98	106.87	77.82	52.26
Price / Book	1.58	16.29	12.89	6.14
Net Income	$13.27M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-1.85%	0.34%	0.61%	-0.27%
1 Month Performance	-3.38%	8.52%	5.73%	0.68%
1 Year Performance	64.60%	52.66%	25.37%	14.84%

SAB Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SABS SAB Biotherapeutics	2.1845 of 5 stars	$3.72 -0.8%	$12.00 +222.6%	+60.3%	$341.20M	$1.32M	N/A	140
MNKD MannKind	2.1985 of 5 stars	$4.16 +2.2%	$9.22 +121.6%	-28.1%	$1.31B	$348.97M	N/A	400
MLTX MoonLake Immunotherapeutics	1.8024 of 5 stars	$15.56 +1.2%	$24.57 +57.9%	-74.5%	$1.31B	N/A	N/A	2	Positive News
ODTX Odyssey Therapeutics	3.6608 of 5 stars	$26.23 +4.3%	$33.00 +25.8%	N/A	$1.21B	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	3.0779 of 5 stars	$14.56 +3.3%	$33.33 +128.9%	+160.7%	$1.19B	N/A	N/A	30	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SABS) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SAB Biotherapeutics (SABS) Competitors

SABS vs. MNKD, MLTX, ODTX, CRVS, and GLUE

How does SAB Biotherapeutics compare to MannKind?

Summary

How does SAB Biotherapeutics compare to MoonLake Immunotherapeutics?

Summary

How does SAB Biotherapeutics compare to Odyssey Therapeutics?

Summary

How does SAB Biotherapeutics compare to Corvus Pharmaceuticals?

Summary

How does SAB Biotherapeutics compare to Monte Rosa Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS vs. The Competition

SAB Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SAB Biotherapeutics (SABS) Competitors

SABS vs. MNKD, MLTX, ODTX, CRVS, and GLUE

How does SAB Biotherapeutics compare to MannKind?

Does the media prefer SABS or MNKD?

Is SABS or MNKD more profitable?

Which has higher valuation & earnings, SABS or MNKD?

Do analysts rate SABS or MNKD?

Do insiders & institutionals believe in SABS or MNKD?

Which has more volatility & risk, SABS or MNKD?

Summary

How does SAB Biotherapeutics compare to MoonLake Immunotherapeutics?

Is MLTX or SABS more profitable?

Do insiders and institutionals have more ownership in MLTX or SABS?

Do analysts rate MLTX or SABS?

Does the media refer more to MLTX or SABS?

Which has higher earnings and valuation, MLTX or SABS?

Which has more volatility and risk, MLTX or SABS?

Summary

How does SAB Biotherapeutics compare to Odyssey Therapeutics?

Does the media prefer SABS or ODTX?

Do institutionals & insiders hold more shares of SABS or ODTX?

Which has stronger earnings & valuation, SABS or ODTX?

Do analysts rate SABS or ODTX?

Is SABS or ODTX more profitable?

Summary

How does SAB Biotherapeutics compare to Corvus Pharmaceuticals?

Do analysts rate CRVS or SABS?

Is CRVS or SABS more profitable?

Does the media favor CRVS or SABS?

Which has better earnings & valuation, CRVS or SABS?

Do institutionals and insiders hold more shares of CRVS or SABS?

Which has more risk and volatility, CRVS or SABS?

Summary

How does SAB Biotherapeutics compare to Monte Rosa Therapeutics?

Is GLUE or SABS more profitable?

Which has stronger earnings and valuation, GLUE or SABS?

Which has more volatility & risk, GLUE or SABS?

Do analysts prefer GLUE or SABS?

Do insiders and institutionals hold more shares of GLUE or SABS?

Does the media favor GLUE or SABS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS vs. The Competition

SAB Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools